Japan Pharma Outlook 2015: 2015 –Year to Watch out for Authorized Generics (AGs), Biosimilars and Overseas Strategic Initiatives

The new pricing system adopted in Japan from April -2014 (Annexure 1) is a game changer initiative.  It pains most of the companies - whether generic or innovator.  The most of the companies are revalidating their domestic (and thus overseas) strategies to adopt with new regulations.